New malaria vaccine shows promise in early human trial
NCT ID NCT02014727
First seen Jan 07, 2026 · Last updated Jun 17, 2026 · Updated 26 times
Summary
This study tested a new malaria vaccine in 66 healthy adults from Europe and Africa. The vaccine aims to teach the body to fight the malaria parasite. Researchers checked for side effects and measured immune responses after three doses over six months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA, FALCIPARUM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIC BT 505 de vaccinologie Cochin Pasteur. Hôpital Cochin Bâtiment Lavoisier 27 rue du faubourg St Jacques.
Paris, 75014, France
-
CNRFP
Ouagadougou, Ouagadougou, Burkina Faso
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.